# GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

> **NCT05023109** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Biliary Tract Carcinoma

## Interventions

- **DRUG:** GP+PD-1+Tight

## Key facts

- **NCT ID:** NCT05023109
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2023-01-18
- **Final completion:** 2024-12-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-08-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05023109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05023109, "GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05023109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*